Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AAB-003 | PF-05236812 | Alzheimer's Disease (Discontinued) | Janssen, Pfizer | Amyloid-Related | Immunotherapy (passive) | |
| ABBV-916 | N3pG-Abeta mAb | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) | ||
| Aduhelm | Aducanumab, BIIB037 |
Alzheimer's Disease (Approved) | Biogen, Neurimmune | Amyloid-Related | Immunotherapy (passive) | |
| ALIA-1758 | Alzheimer's Disease (Phase 1) | AbbVie, Aliada Therapeutics | Amyloid-Related | Immunotherapy (passive) | ||
| Bapineuzumab | AAB-001 | Alzheimer's Disease (Discontinued) | Janssen, Pfizer | Amyloid-Related | Immunotherapy (passive) | |
| Crenezumab | MABT5102A , RG7412 |
Alzheimer's Disease (Discontinued) | AC Immune SA, Genentech, Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | None |
| DNL919 | TAK-920, ATV:TREM2 |
Alzheimer's Disease (Discontinued) | Denali Therapeutics Inc., Takeda Pharmaceutical Company | Amyloid-Related, Inflammation | Immunotherapy (passive) | |
| Gammagard® | Intravenous Immunoglobulin, IVIg |
Alzheimer's Disease (Discontinued) | Baxter Healthcare | Amyloid-Related, Inflammation | Immunotherapy (passive) | Immunodeficiency conditions |
| Gamunex | Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma |
Alzheimer's Disease (Phase 2/3) | Grifols Biologicals Inc. | Amyloid-Related, Inflammation | Combination, Immunotherapy (passive) | Immunodeficiency, chronic inflammatory demyelinating neuropathy |
| Gantenerumab | RO4909832, RG1450, R1450 |
Alzheimer's Disease (Discontinued) | Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | |
| GSK933776 | Alzheimer's Disease (Inactive) | GlaxoSmithKline (GSK) | Amyloid-Related | Immunotherapy (passive) | ||
| IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
| Kisunla | Donanemab, LY3002813, N3pG-Aβ Monoclonal Antibody |
Alzheimer's Disease (Approved) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | |
| Leqembi | Lecanemab-irmb, BAN2401, mAb158 |
Alzheimer's Disease (Approved) | BioArctic AB, Biogen, Eisai Co., Ltd. | Amyloid-Related | Immunotherapy (passive) | |
| LY2599666 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | ||
| MEDI1814 | Alzheimer's Disease (Phase 1) | AstraZeneca, Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | ||
| Octagam®10% | Intravenous Immunoglobulin, NewGam |
Alzheimer's Disease (Inactive), Mild Cognitive Impairment (Inactive) | Octapharma | Amyloid-Related, Inflammation | Immunotherapy (passive) | Immunodeficiency disorders |
| PMN310 | Alzheimer's Disease (Phase 1) | ProMIS Neurosciences, Inc. | Amyloid-Related | Immunotherapy (passive) | ||
| Ponezumab | PF-04360365 | Alzheimer's Disease (Discontinued), Cerebral Amyloid Angiopathy (Discontinued) | Pfizer | Amyloid-Related | Immunotherapy (passive) | None |
| PRX012 | Alzheimer's Disease (Phase 1) | Prothena | Amyloid-Related | Immunotherapy (passive) | ||
| Remternetug | LY3372993, N3pG-Abeta mAb |
Alzheimer's Disease (Phase 3) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | |
| Sabirnetug | ACU-193 | Alzheimer's Disease (Phase 2/3) | Acumen Pharmaceuticals, Inc. | Amyloid-Related | Immunotherapy (passive) | |
| SAR228810 | Alzheimer's Disease (Discontinued) | Sanofi | Amyloid-Related | Immunotherapy (passive) | ||
| SHR-1707 | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) | |||
| Solanezumab | LY2062430 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | None |
| Trontinemab | RO7126209, RG6102 , Brain shuttle gantenerumab |
Alzheimer's Disease (Phase 1/2) | Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) |